Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology
Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products
AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch
ORLANDO, FL / ACCESSWIRE / September 24, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for patent application entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology.
The Aversa™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, Australia, and China.
Nutriband's AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. Preliminary studies have shown that the coating is very difficult to scrape off and the technology has a patented immediate and extended-release profile which presents an additional layer of deterrence to prevent the aversive layer from easily being washed off in an attempt to separate the drug from the aversive agents.
Nutriband is currently working with its partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA™ Fentanyl, which incorporates Nutriband's AVERSA™ abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach annual US sales of $80 million to $200 million.1
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q's filed subsequent to the Form 10-K in 2024, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Investor Relations
RedChip Companies, Inc.
Dave Gentry
Email: NTRB@Redchip.com
Phone: 1-800-RED-CHIP (733-2447)
or 407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband, Inc.
View the original press release on accesswire.com
Nutriband, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata Reports First Quarter 2025 Results with Revenue up 120% Year-Over-Year and Reaffirms Growth Guidance of 40% or more for 20258.5.2025 16:45:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2025. Revenue of $58.3 million, representing 120% revenue growth year-over-year. Adjusted EBITDA of $12.7 million, an increase of $8.9 million from $3.8 million in the same period last year.* Net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, compared to a net income of $1.0 million, or $0.03 per basic and diluted share, in the same period last year. Cash, cash equivalents and short-term investments were $56.6 million as of March 31, 2025 and $46.9 million as of December 31, 2024. * Adjusted EBITDA is defined below. Jack Abuhoff, CEO, said, "We had a strong start to the year. We're being onboarded by potential major new customers, expanding existing relationships, and building a pipeline that's deeper and more advanced than at any point in our history. We are bringing ideas and innovation to our customers that are being w
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft8.5.2025 12:00:00 CEST | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 8, 2025 / The UK's Military Aviation Authority has issued a Military Type Certificate to the Royal Air Force's Protector RG Mk1 uncrewed aircraft, also designated the MQ-9B, certifying that it has passed a rigorous airworthiness assessment and verifying it's safe to operate without geographic restrictions, including over populous areas. This April 29 decision was a first-of-its-kind milestone for a large, unmanned aircraft system. It's a huge accomplishment for the UK and a technological watershed in the history of unmanned aircraft systems. GA-ASI is the first manufacturer of large, unmanned aircraft to receive an MTC based on rigorous compliance with STANAG 4671, the NATO standard for unmanned aircraft system airworthiness. Obtaining the MTC has been a goal of GA-ASI since the inception of the MQ-9B in January 2014. The company took its proven UAS platform, the MQ-9A, and added performance enhancing features while ensuring that the design
The Battery Show Europe 2025 Critical Agenda Highlights Moves to Global Collaboration, Regulation and Supply Chain Resilience8.5.2025 04:00:00 CEST | Press release
Featuring speakers from BMW, CATL, Mercedes Benz, Cellforce and more. STUTTGART, GERMANY / ACCESS Newswire / May 8, 2025 / The Battery Show Europe and Electric & Hybrid Vehicle Technology Expo Europe, co-located with Energy Storage Summit Germany, the region's only dedicated event for battery manufacturing, electric and hybrid vehicle tech industries, has announced its 2025 keynote lineup. The sessions will cover key themes including upcoming supply chain, navigating regulatory and policy changes and staying ahead of the curve on market trends with analysis. "Better Together: Building Resilient Battery Supply Chains Through International Collaboration," opens the program moderated by James Frith, Principal at Volta Energy Technologies, featuring insights from Isobel Sheldon, Global CEO at Western CAM Inc, Ulderico Ulissi, Head of Overseas Tech & Start-up Cooperation at CATL, Jerry Fang, Director of Business Development at Shanghai Putailai New Energy Technology Co., Ltd. and Benoit Lem
Aster Guardians Global Nursing Award Unveils Top 10 Finalists for 2025 from 100,000+ Registrations7.5.2025 10:30:00 CEST | Press release
Over 100,000 registrations received from nurses across 199* countries - a 28% increase from the third edition, which received 78,000+ registrations. One of the shortlisted Top 10 finalists will be honoured with the grand title award and a prize of USD 250,000. These finalists were selected following a rigorous evaluation process, led by esteemed expert jury and grand jury panels. The entire process is independently moderated by the appointed "Process Advisors" Ernst & Young LLP. DUBAI, AE / ACCESS Newswire / May 7, 2025 / Aster DM Healthcare has today announced the Top 10 finalists for the fourth edition of Aster Guardians Global Nursing Award - a prestigious global recognition with USD 250,000 prize money, that honours the exceptional contributions of nurses worldwide. These 10 finalists were selected from a record-breaking pool of 100,000+ registrations across 199* countries, through a stringent evaluation process led by expert jury and Grand jury panels members. The entire process i
StrikeX and CMC Markets Enter New Growth Phase With Majority Acquisition7.5.2025 06:00:00 CEST | Press release
LONDON, GB / ACCESS Newswire / May 7, 2025 / StrikeX is pleased to announce a landmark new agreement with CMC Markets, the award-winning* FTSE250 financial services provider. As part of this expanded collaboration, CMC Markets has taken a controlling 51% stake in StrikeX Technologies Ltd., up from its previous 33% shareholding. Additionally, CMC has increased its holdings of the STRX token from 10 million to 15 million.StrikeX and CMC Markets This deal marks a significant evolution in the relationship between the two companies - a move that not only signals CMC's deepened confidence in StrikeX's vision, but also establishes a new strategic foundation for long-term growth and innovation in the digital asset space. Joe Jowett, CEO and Co-Founder of StrikeX, shared his enthusiasm for the development, stating: "This agreement represents a major step forward for StrikeX. CMC Markets' decision to increase their investment and take a controlling stake reflects a shared commitment to building
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom